{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:25:15Z","timestamp":1790367915816,"version":"4.1.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"21","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>In chronic kidney disease (CKD), the design of the parenteral nutrition (PN) regimen becomes more challenging where only individualized PN is appropriate, coupled with the increased risk of unintended interactions with diuretic therapy. In an effort to ensure safe therapy in the home, we assessed the physical stability of bespoke PN formulations intended for use in CKD in the simultaneous presence of Y-site compatibility of furosemide and torasemide. The patient's daily needs were determined based on both metabolic demands as well as the demand for fluids.<\/jats:p>\n            <jats:p>Complete admixtures were subjected to physical stability analysis consisting of visual inspection, a validated light microscope method, pH measurement, zeta potential measurement, and characterization of oily globule size distribution. Y-site compatibility of furosemide and torasemide with the formulated admixtures was also performed.<\/jats:p>\n            <jats:p>The total parenteral admixture was stable over 7 days at +4\u00b0C and 24\u200ah at +25\u00b0C and compatible via the Y-line together with furosemide and torasemide over 12\u200ah at +25\u00b0C.<\/jats:p>\n            <jats:p>The stability assessment guarantees the safety and efficiency of home PN with loop diuretics therapy in CKD patients. This means that these patients do not need long hospitalization and they can be safely treated at home. Furthermore, this study proved that torasemide is the same safety diuretic as furosemide, which has a great impact on clinical practice.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000015747","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T12:23:52Z","timestamp":1558614232000},"page":"e15747","source":"Crossref","is-referenced-by-count":10,"title":["Evaluation of Y-site compatibility of home total parenteral nutrition and intravenous loop diuretics"],"prefix":"10.1097","volume":"98","author":[{"given":"Dorota","family":"Watrobska-Swietlikowska","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Technology, Medical University of Gdansk, Gdansk"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Pietka","sequence":"additional","affiliation":[{"name":"General Surgery and Oncology Unit, Stanley Dudrick's Memorial Hospital, Skawina, Poland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislaw","family":"Klek","sequence":"additional","affiliation":[{"name":"General Surgery and Oncology Unit, Stanley Dudrick's Memorial Hospital, Skawina, Poland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.nut.2014.02.001","article-title":"Renal function in patients on long-term home parenteral nutrition and in intestinal transplant recipients","volume":"30","author":"Pironi","year":"2014","journal-title":"Nutrition"},{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1471-2369-15-55","article-title":"Metabolic acidosis and the progression of chronic kidney disease","volume":"15","author":"Chen","year":"2014","journal-title":"BMC Nephrol"},{"key":"R3-20230914","first-page":"251","article-title":"Nutritional support teams: the cooperation among physicians and pharmacists helps improve cost-effectiveness of home parenteral nutrition (HPN)","volume":"31","author":"Pietka","year":"2015","journal-title":"Nutr Hosp"},{"key":"R4-20230914","first-page":"7","article-title":"Parenteral nutrition in patients with renal failure: Guidelines on Parenteral Nutrition, Chapter 17","author":"Druml","year":"2009","journal-title":"Ger Med Sci"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.clnu.2009.05.016","article-title":"Guidelines on parenteral nutrition: adult renal failure","volume":"28","author":"Cano","year":"2009","journal-title":"Clin Nutr"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12882-016-0280-0","article-title":"Low-protein diets for chronic kidney disease patients: the Italian experience","volume":"17","author":"Bellizzi","year":"2016","journal-title":"BMC Nephrol"},{"key":"R7-20230914","article-title":"Effects of parenteral infusion of amino acid solutions in acid-base balance in patients with advanced chronic renal failure","author":"Kalogiannidou","year":"2011","journal-title":"J Nephrol Therapeutic"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12937-016-0149-x","article-title":"Development and evaluation of a test program for Y-site compatibility testing of total parenteral nutrition and intravenous drugs","volume":"15","author":"Staven","year":"2016","journal-title":"Nutr J"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1365-2044.2009.06228.x","article-title":"Benefits and risks of furosemide in acute kidney injury","volume":"65","author":"Ho","year":"2010","journal-title":"Anaesthesia"},{"key":"R10-20230914","first-page":"7","article-title":"Torsemide and furosemide: similarities and differences","volume":"7","author":"Kuch","year":"2014","journal-title":"Medycyna Faktow"},{"key":"R11-20230914","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5049\/EBP.2015.13.1.17","article-title":"Loop diuretics in clinical practice","volume":"13","author":"Se","year":"2015","journal-title":"Electrolyte Blood Press"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1345\/aph.1M177","article-title":"A comprehensive review of the loop diuretics: should furosemide be first line?","volume":"43","author":"Wargo","year":"2009","journal-title":"Ann Pharmacother"},{"key":"R13-20230914","article-title":"Managing drug therapy in patients receiving enteral and parenteral nutrition","author":"Thomson","year":"2000","journal-title":"Pharm J"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.clnu.2009.04.001","article-title":"ESPEN Guidelines on parenteral nutrition: home parenteral nutrition (HPN) in adult patients","volume":"28","author":"Staun","year":"2009","journal-title":"Clin Nutr"},{"key":"R15-20230914","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/014860719902300267","article-title":"Compatibility of medications with 3-in-1 parenteral nutrition admixtures","volume":"23","author":"Trissel","year":"1999","journal-title":"J Parenter Enteral Nutr"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201905240-00033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T19:48:37Z","timestamp":1694720917000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201905240-00033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":15,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000015747","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}